98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188327 | PMC |
http://dx.doi.org/10.1002/ueg2.12753 | DOI Listing |
AMB Express
July 2025
Department of Parasitology and Mycology, Skin Diseases and Leishmaniasis Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Bifidobacterium bifidum (B. bifidum) anti-inflammatory characteristics and ability to modify the gut microbiota make it a promising treatment option for Inflammatory Bowel Disease (IBD). The present study investigated the modulatory effects of B.
View Article and Find Full Text PDFUnited European Gastroenterol J
June 2025
Serviço de Doenças Infeciosas, Hospital de São joão, Unidade Local de Saúde de São João, Porto, Portugal.
United European Gastroenterol J
June 2025
Gastroenterology Department, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Hospital General Universitario Dr Balmis de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Madrid, Spain.
Background: Leishmaniasis (LI) is a vector-borne illness caused by a protozoan of the genus Leishmania. Data on the features of LI in patients with inflammatory bowel disease (IBD) are scarce.
Aim: To describe the characteristics of patients with IBD who present with leishmaniasis, infection outcomes and the risk factors associated with developing visceral leishmaniasis (VL).
Acta Parasitol
December 2024
Department of Parasitology and Mycology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Gastroenterol Hepatol
January 2024
Servicio de Aparato Digestivo, Hospital Universitario la Fe de Valencia, Valencia, España.
Infection by Leishmania spp. in patients diagnosed with inflammatory bowel disease (IBD) is rare. Considered endemic in the Mediterranean basin, its manifestations are almost exclusive of patients with impaired cellular immunity.
View Article and Find Full Text PDF